Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics
ZNTL Price/Volume Stats
Current price | $15.76 | 52-week high | $31.46 |
Prev. close | $15.19 | 52-week low | $9.56 |
Day low | $15.22 | Volume | 580,000 |
Day high | $16.08 | Avg. volume | 825,152 |
50-day MA | $13.46 | Dividend yield | N/A |
200-day MA | $18.60 | Market Cap | 1.12B |
ZNTL Stock Price Chart Interactive Chart >
Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
Latest ZNTL News From Around the Web
Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on December 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 42,000 shares of the Company’s common stock and 28,0 |
David Johnson Bought 16% More Shares In Zentalis PharmaceuticalsInvestors who take an interest in Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) should definitely note that the... |
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc SharesIn the realm of stock market movements, insider trading activity is often a significant indicator that investors monitor to gauge the confidence of management and key stakeholders in the company's future. |
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD CowenInvestor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, toda |
ZNTL Price Returns
1-mo | 1.74% |
3-mo | 4.03% |
6-mo | -21.44% |
1-year | -5.23% |
3-year | -60.90% |
5-year | N/A |
YTD | 4.03% |
2023 | -24.78% |
2022 | -76.04% |
2021 | 61.84% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...